Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 10Phase 1 5Phase 3 2Phase NA 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Sarcoma, Ewing 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Jaundice 1Endocrine Gland Neoplasms 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Interventional × ganitumab × Clear all
NCT02306161 2026-06-03

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
312 enrolled 14 charts
Sarcoma

Sarcoma, Ewing

NCT01231347 2024-07-16

GAMMA

NantCell, Inc.

Phase 3 Completed
800 enrolled 11 charts
Gastrointestinal

Endocrine Gland Neoplasms, Jaundice, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡